Loading...

FITC anti-mouse CD4 Antibody

Pricing & Availability
Clone
RM4-5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RM4-5
C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) FITC (solid line) or rat IgG2a, κ FITC isotype control (dotted line).
  • RM4-5
    C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) FITC (solid line) or rat IgG2a, κ FITC isotype control (dotted line).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100509 50 µg 24€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100510 500 µg 80€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References

(PubMed link indicates BioLegend citation)
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Xu C, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.071. PubMed
  2. Wang L, et al. 2018. Exp Ther Med. 15:1532. PubMed
  3. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  4. Yu HH, et al. 2021. J Am Heart Assoc. 10:e023077. PubMed
  5. Stone VM, et al. 2022. iScience. 25:105070. PubMed
  6. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  7. Fachi JL et al. 2019. Cell reports. 27(3):750-761 . PubMed
  8. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  9. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  10. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  11. Gilleron J et al. 2018. Cell reports. 25(12):3329-3341 . PubMed
  12. Moodley D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9852 - 9857. PubMed
  13. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  14. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  15. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  16. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  17. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  18. Li ZX, et al. 2022. Arch Virol. :. PubMed
  19. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  20. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  21. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  22. Lin H, et al. 2020. Front Microbiol. 1.330555556. PubMed
  23. Ogawa M, et al. 2019. J Biol Methods. 5:e102. PubMed
  24. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  25. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  26. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  27. Jin X, et al. 2019. Mol Cell. 73:22:00. PubMed
  28. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  29. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  30. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  31. Sehnert B, et al. 2022. Front Immunol. 13:921488. PubMed
  32. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  33. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  34. Yi M, et al. 2021. J Hematol Oncol. 14:27. PubMed
  35. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  36. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  37. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  38. Forni MF, et al. 2021. Front Oncol. 11:667715. PubMed
  39. Graham DB, et al. 2018. Nat Med. 24:1762. PubMed
  40. Terashima Y, et al. 2020. Nat Commun. 11:609. PubMed
  41. Sundberg T, et al. 2014. Proc Natl Acad Sci U S A. 111:12468. PubMed
  42. Wiesner D, et al. 2015. PLoS Pathog. 11:1004701. PubMed
  43. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  44. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  45. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  46. Qi X, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.25. PubMed
  47. Zhang L, et al. 2021. Methods Mol Biol. 2388:175. PubMed
  48. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  49. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  50. Liao T, et al. 2017. Front Immunol. 8:1334. PubMed
  51. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  52. Mencarelli A, et al. 2016. Sci Rep. 6:30802. PubMed
  53. Gozgit JM, et al. 2021. Cancer Cell. :. PubMed
  54. Duan RN, et al. 2021. J Neuroinflammation. 18:145. PubMed
  55. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  56. Wan X, et al. 2018. Nature. 560:107. PubMed
  57. Wheeler MA, et al. 2019. Cell. 176:581. PubMed
  58. Zhang YN, et al. 2020. EBioMedicine. 56:102819. PubMed
  59. Sebastian M, et al. 2016. J Immunol. 196: 144 - 155. PubMed
  60. Fang E, et al. 2022. MedComm (2020). 3:e117. PubMed
  61. Belgiovine C, et al. 2021. Eur J Immunol. 51:2677. PubMed
  62. Takeshita Y, et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8:. PubMed
  63. Kulkarni R, et al. 2021. PLoS One. 16:e0257191. PubMed
  64. Lischke T, et al. 2013. Infect Immun . 81:4091. PubMed
  65. Alhosaini K, et al. 2021. Brain Sci. :11. PubMed
  66. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  67. Su X, et al. 2022. J Transl Med. 20:378. PubMed
  68. Anger-Góra N, et al. 2021. Oncol Lett. 22:582. PubMed
  69. Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed
  70. Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed
  71. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  72. Lü X, et al. 2021. Exp Ther Med. 22:1005. PubMed
  73. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  74. Aguilera M, et al. 2021. Int J Mol Sci. 22:. PubMed
  75. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  76. Kyburz A, et al. 2017. Clin Exp Allergy. 47:1331. PubMed
  77. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  78. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  79. Tu J, et al. 2022. Mol Ther Nucleic Acids. 27:733. PubMed
  80. Kim M, et al. 2018. Immunity. 49:151. PubMed
  81. Papa I, et al. 2017. Nature. 547:318. PubMed
  82. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  83. Zhang J, et al. 2018. Nature. 553:91. PubMed
  84. Zhou X, et al. 2021. Cell Reports. 34(1):108601. PubMed
  85. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  86. Takenori Inomata, Jing Hua, Antonio Di Zazzo 2016. Sci Rep. 6:39924. PubMed
  87. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  88. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  89. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
  90. Uribe-Herranz M, et al. 2018. JCI Insight. 3. PubMed
  91. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  92. Richardson ET, et al. 2015. PLoS One. 10: 1371. PubMed
  93. Unsinger J, et al. 2021. J Leukoc Biol. 109:697. PubMed
  94. Bao Z, et al. 2020. Ann Transplant. 25:e921287. PubMed
  95. Cantor DJ et al. 2019. Cell reports. 26(1):108-118 . PubMed
  96. Bell CR, et al. 2022. Nat Commun. 13:2063. PubMed
  97. de Assis LVM, et al. 2022. Commun Biol. 5:461. PubMed
  98. Zegarra‐Ruiz DF et al. 2018. Cell host & microbe. 25(1):113-127 . PubMed
  99. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  100. Lu J, et al. 2022. Int J Mol Med. 49:. PubMed
  101. Harrison DK, et al. 2021. Transplantation. 105:540. PubMed
  102. Leon-Ponte M, et al. 2006. Blood. 109:3139. PubMed
  103. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  104. Yeon S, et al. 2017. Sci Rep. 10.1038/s41598-017-11492-7. PubMed
  105. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  106. Baptista M, et al. 2016. Nat Commun. 7:12175. PubMed
  107. Wang X, et al. 2022. Elife. 11:. PubMed
  108. Krotova K, et al. 2019. Mol Ther Oncolytics. 15:166. PubMed
  109. Helfricht A, et al. 2020. J Exp Med. 217:00:00. PubMed
  110. Ren D, et al. 2020. Am J Cancer Res. 2851:10. PubMed
  111. Wheeler MA, et al. 2020. Nature. 578:593. PubMed
  112. Siegmund K, et al. 2011. J Immunol. 186:3452. PubMed
  113. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
  114. Gonzalez-Figueroa P, et al. 2021. Cell. 184(7):1775-1789.e19. PubMed
  115. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  116. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  117. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  118. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  119. Ren X, et al. 2021. Cell Death Dis. 12:484. PubMed
  120. Rana MN, et al. 2021. Front Pharmacol. 12:643215. PubMed
RRID
AB_312712 (BioLegend Cat. No. 100509)
AB_312713 (BioLegend Cat. No. 100510)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 3    Revision Date: 01.29.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account